Overview

The Bihormonal iLet Bionic Pancreas Feasibility Study

Status:
Completed
Trial end date:
2019-07-03
Target enrollment:
Participant gender:
Summary
Our objective is to evaluate the function of the bihormonal configuration of the ILet bionic pancreas delivering dasiglucagon when compared to the insulin-only configuration of the ILet bionic pancreas in a home-use study in adults with type 1 diabetes.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beta Bionics, Inc.
Zealand Pharma
Treatments:
Glucagon
Glucagon-Like Peptide 1
Insulin
Insulin, Globin Zinc
Pancreatin
Pancrelipase